Innovative Personalized Cancer Vaccine for Dog Created Using AI

Paul Conyngham, a tech entrepreneur from Sydney, faced a daunting diagnosis when veterinarians informed him that his rescue dog, Rosie, had only a few months to live. Not one to accept the prognosis blindly, Conyngham, who has a strong background in data science but no formal biology training, decided to leverage AI tools, particularly ChatGPT. His goal? To create a personalized cancer vaccine for Rosie, a step no one had previously taken.

Rosie was diagnosed with advanced mast cell cancer in 2024. While chemotherapy managed to slow down the cancer’s progression, it didn’t reduce the size of her tumors. In response, Conyngham invested about $3,000 to have both Rosie’s healthy and tumor DNA sequenced at the University of New South Wales. He then utilized various AI systems, like AlphaFold, to identify the mutations responsible for her cancer and to find potential drug targets.

“We sequenced her tumor DNA, converted that from tissue to data, and then used it to identify the issue in her DNA to develop a cure,” Conyngham explained during an interview on Australia’s Today Show. He noted that ChatGPT was instrumental throughout the whole process.

After encountering a roadblock with a pharmaceutical company that declined to provide a promising immunotherapy drug for compassionate use, he shifted gears. Collaborating with UNSW’s RNA Institute, Conyngham worked on manufacturing a custom mRNA vaccine based on the AI-generated formula.

Just two months after finalizing the DNA sequence, Rosie received her first vaccine injection in December. By mid-March, the tennis ball-sized tumor on her leg had remarkably shrunk by about 75%, as reported by Conyngham during his March 15 appearance on the Today Show.

“At the beginning of December, her mobility was severely compromised, and she seemed to be fading,” he shared with The Australian. “But by the end of January, she was energetically jumping over fences to chase rabbits.”

Researchers at UNSW have indicated that this marks the first personalized cancer vaccine ever created for a dog. Martin Smith, director of the UNSW Ramaciotti Centre for Genomics, raised an important issue: “If we can do this for a dog, why isn’t this being implemented for all humans with cancer?”

Páll Thordarson, director of the UNSW RNA Institute, underscored the significance of this achievement. “This is the first tailored cancer vaccine designed for a dog… Ultimately, we aim to use this approach to assist humans,” he commented. He also added that Conyngham’s ability to generate an mRNA recipe without any formal biology education illustrates how this technology is democratizing the entire process.

Rosie’s situation stands out, but for investors, it sends a compelling signal: the same mRNA platform technology is currently being tested in several human clinical trials, managed by major pharmaceutical companies. They are approaching potential regulatory approvals with some of the most advanced programs already in the pipeline.

Companies like Moderna and Merck are at the forefront of this shift. Together, their personalized melanoma vaccine, now known as intismeran autogene, reportedly shows a 49% reduction in the risk of cancer recurrence or death when combined with Merck’s widely-used immunotherapy drug, Keytruda, based on data released in January 2026. The sustained effectiveness of the vaccine over five years indicates that it continues to train the immune system to monitor for cancer cells even beyond the treatment period.

Currently, Phase 3 trials are underway for melanoma and non-small-cell lung cancer, with interim results expected later this year. Additional Phase 2 studies are also ongoing in kidney and bladder cancers. Analysts estimate that the new vaccine could be priced similarly to Keytruda, around $200,000 per patient, and may generate multibillion-dollar peak sales just in melanoma treatment.

BioNTech, known for the Pfizer COVID vaccine, is also running its own mRNA cancer vaccine program in collaboration with Genentech. Their personalized vaccine, autogene cevumeran, displayed lasting immune responses in a Phase 1 trial for pancreatic cancer, with some patients showing delayed tumor recurrence compared to non-responders.

As of now, a larger Phase 2 trial is recruiting participants globally, and BioNTech is testing mRNA vaccines for other cancers, although it’s lagging behind Moderna’s oncology programs.

Overall, there have been more than 400 clinical trials focused on various types of cancer vaccines initiated worldwide in the last three years, as per data from the National Library of Medicine. About 120 of these specifically involve mRNA-based approaches. The broader mRNA therapeutics market was valued at approximately $7.7 billion in 2025 and is projected to grow significantly as oncology programs progress.

Moderna has been pivoting towards oncology, with its personalized cancer vaccine now being the centerpiece of its growth narrative, especially following a significant decline in revenue from COVID vaccine sales. Although there’s potential, the uncertainty persists, especially after Moderna faced challenges with the FDA regarding its flu vaccine submissions, though it later accepted an amended application.

With some experimental hurdles ahead, including the need to custom-manufacture each vaccine for individual patients and the associated high costs, scaling this process remains a significant logistical challenge. Finding a viable commercial pathway for such personalized treatments is still a work in progress.

What Conyngham demonstrated with Rosie—transforming tumor biopsy data into a custom mRNA treatment using AI—mirrors the large-scale efforts of companies like Moderna and BioNTech, which are investing substantially to industrialize similar processes for human patients.

While there’s no definitive cure yet—one of Rosie’s tumors wasn’t responsive, prompting the team to devise a second vaccine—the advances in AI drug design and decreasing sequencing costs are pushing personalized cancer vaccines closer to becoming a clinical reality. For investors, the critical question isn’t merely whether this technology is effective; the focus is on which companies can successfully scale it, navigate complex regulations, and transform individualized treatments into commercially viable products. That competition is already underway.

As for Rosie? She’s still with us—leaping over fences, chasing rabbits, and standing as evidence that, sometimes, a determined individual with a laptop and a dream can make a significant impact in ways that few could anticipate.